Inhaled nicotine replacement therapy  by Cipolla, David & Gonda, Igor
Review
Inhaled nicotine replacement therapy
David Cipolla *, Igor Gonda
Aradigm Corp, 3929 Point Eden Way, Hayward, CA 94545, USA
A R T I C L E I N F O
Article history:
Received 1 June 2015
Received in revised form 11 July
2015
Accepted 13 July 2015
Available online 28 August 2015
A B S T R A C T
There are a large number of smokers who want to quit smoking but have failed in their
attempts to do so, with many having been unsuccessful at quitting multiple times over their
lifetime. The existing marketed nicotine replacement therapies (NRT) have only marginal
effectiveness and none provide a comparable physiological response to that derived from
cigarette smoking; that is, rapid absorption of nicotine from the lung leading to peak levels
of nicotine in the bloodstream to target the receptors in the brain. Instead, existing NRTs
produce a slower and delayed rise in nicotine blood levels which is less effective at reduc-
ing the craving sensations. Published data for electronic cigarettes show that they typically
deliver nicotine with a profile closer to that for nicotine patches, with a slow rise that can
take 30–60 min, or longer, to reach the same peak nicotine concentration that is produced
in less than 3 min from a single cigarette. A number of attempts have been made to develop
an inhaled product which would deliver the nicotine through the lung and mimic the physi-
ological response from smoking, but many of them produced intolerable aversive reactions
or delivered an ineffective dose.This paper discusses examples of the potential for the recent
inhaled nicotine products in development to be effective as NRTs, but is not meant to be a
comprehensive review.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Shenyang Phar-
maceutical University. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
Keywords:
Nicotine
Smoking cessation
Inhalation delivery
AERx system
Staccato
Voke inhaler
1. Introduction
Cigarette smoking is harmful, often leading to early mortality,
and represents a huge public health problem. At present, ciga-
rette smoking causes more than 480,000 deaths annually in the
US, accounting for about one in five deaths, with an estimated
41,000 of these deaths resulting from secondhand smoke [1].
Smoking is the leading cause of death in the US among the pre-
ventable risk factors, which include smoking, unhealthy diet,
physical inactivity and sexual behavior; smoking kills more
people than AIDS, alcohol, illegal drug abuse, homicides, car ac-
cidents, and suicide combined (Fig. 1). The issue is even more
acute in Asia. Over 300 million smokers reside in China repre-
senting more than a third of the smokers worldwide [3]. Men
account for 96% of the smokers in China with 52.9% of men and
2.4% of women identified as smokers [3]. One million deaths in
China are attributable to cigarettes yearly and this is projected
to increase three-fold by 2050 if smoking rates do not change
[3]. Worldwide, tobacco use causes nearly 6 million deaths/y.
Current trends show that tobacco will causemore than 8million
deaths annually on a worldwide basis by 2030 [4].
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In theUS,smoking causes about 90%of all lung cancer deaths
in men, and about 80% of all lung cancer deaths in women [5].
However, the ill effects from smoking are not limited to the
lung. Cigarette smoking can cause cancer almost anywhere in
the body, including the bladder, bone, blood, cervix, esopha-
gus, kidney, larynx, mouth, nose, throat, pancreas, stomach,
and trachea. If nobody smoked, it is estimated that one of every
three cancer deaths in the US would not happen [5].
Smokers are addicted to nicotine and have great difficulty
quitting smoking. However, it must be emphasized that the
harmful effects of tobacco smoking are largely due to the other
ingredients of tobacco smoke – tar constituents and carbon
monoxide – and not nicotine. Fortunately, many of the effects
of smoking can be reversed or attenuated after quitting and
can add years to the average smoker’s life expectancy [6,7].
Therefore, effective smoking cessation treatment would be
enormously beneficial for individuals as well as a public health
measure.
For people trying to quit smoking, nicotine replacement
therapies (NRTs) on the market today are not very effective at
satisfying the craving for cigarettes [8,9]. Thus, NRTs (e.g.,
patches, lozenges, gums, nasal sprays, and the buccal inhaler)
exhibit very modest long term quitting efficacy, generally <10%.
In a study of 787 adult smokers in Massachusetts who had re-
cently quit smoking and were evaluated over a 5 y period, the
authors concluded that using NRTs is no more effective than
trying to quit without the use of NRTs [8].While clinical studies
have found NRTs to be effective versus placebo, this study pro-
vides empirical evidence regarding the lack of effectiveness
when NRTs are used in the general population [8].
The limited benefit of NRTs is primarily associated with the
relatively slow absorption of nicotine into the bloodstream, and
ultimately its slow uptake into the brain. Thus, existing NRTs
are not an effective substitute for cigarettes as they cannot ac-
tivate the neural reward pathways in the same way that
cigarettes do [9]. Rapid nicotine absorption with a high Cmax
produces a better reduction in craving and may inhibit relapse
[9,10]. Other contributors to relapse may be the absence of the
airway sensation experience for NRTs that occurs during
tobacco smoking, as well environmental cues that can trigger
an urge to smoke; e.g., seeing others smoke or the smell of a
cigarette [9].
Among the NRTs, nicotine nasal sprays have the fastest entry
of nicotine into the bloodstream (Fig. 2); however, the phar-
macokinetics is still not as rapid as that for cigarettes [12].
Furthermore, nicotine nasal sprays deliver relatively high doses
of nicotine to a small surface area within the nasal cavity, which
can lead to irritation and ultimately lack of acceptability.A nico-
tine replacement system which delivers nicotine via the
inhalation route to the lung therefore has the potential to better
satisfy craving and improve quitting rates [9]. While no
pharmaceutically-based inhaled NRT system for delivery of
nicotine to the lung is on the market, a number are in devel-
opment [10,13,14] and these will be the focus of the review. For
the purposes of this article, pharmaceutically-based NRT
systems are defined as those which are manufactured in
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Fig. 1 – US annual deaths attributable to preventable causes
(total = 613,000). The data are for 2009 and are extracted
from Reference 2.
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Fig. 2 – Mean nicotine plasma profiles in humans from cigarettes or NRTs. The data are adapted from Reference 11 for the
Nicotrol inhaler and Reference 12 for the other nicotine delivery systems and cigarettes.
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accordance with good manufacturing processes (GMPs) and ap-
proved by regulatory agencies based on clinical data.
In contrast, a variety of electronic nicotine delivery devices
such as e-cigarettes are already available in many countries
which provide an alternative to cigarettes and a potentially
‘safer’ way to inhale nicotine.These devices are promoted spe-
cifically without clinical data demonstrating that they reduce
cigarette dependence and, as such, they cannot be marketed
as NRTs (at least in the US) but instead as tobacco products
[15]. E-cigarettes are gaining in popularity and may offer some
safety benefits over cigarettes in terms of harm reduction due
to elimination of exposure to carcinogenic tobacco combus-
tion products [16]. However, much is unknown about the long-
term safety of e-cigarette use as well as the safety of
“secondhand” exposure from e-cigarettes. For these reasons
and others, e-cigarettes are banned in many countries and re-
stricted in public places in others.
E-cigarettes contain organic solvents andmany have chemi-
cals as flavorings,with no proven safety data [17].Two additional
concerns are the potential for the nicotine to decompose due
to instability in the e-cigarette formulation and the potential
for unintended poisoning from the concentrated liquid nico-
tine in e-cigarettes [18]. On that note, the Center for Disease
Control (CDC) reported that the proportion of nicotine expo-
sure calls to poison control centers due to e-cigarettes surged
from 0.3% (1 call) in September 2010 to 42% (215 calls) in Feb-
ruary 2014 and furthermore that e-cigarette exposure calls were
more likely to report an adverse event than those for ciga-
rettes [18]. There is also much concern about the use of
e-cigarettes in nicotine-naïve subjects, especially school chil-
dren. However, this usage has surfaced only recently, and the
initial rise of e-cigarette popularity was ostensibly driven by
people who want to quit smoking or reduce cigarette usage
[19]. Unfortunately, there is little evidence that e-cigarettes aid
in either smoking cessation or a reduction in cigarette con-
sumption [19,20]. Even the “efficacy” of e-cigarettes has been
questioned because of the widely variable dosimetry across the
over 250 brands on the market [16,17]; e-cigarettes generally
produce relatively modest peak levels of nicotine compared to
those obtained from cigarettes [9,17].
In contrast, pure nicotine is recognized as safe and non-
carcinogenic and is an approved drug for the chronic treatment
for smoking cessation in the US and EU as well as many other
countries.While tobacco smoke contains ~4000 chemicals, of
which ~250 are harmful, and ~50 are carcinogenic, nicotine itself
is not a direct carcinogen [1,21]. Nicotinemay contribute to some
smoking related diseases, but its contribution is generally con-
sidered much smaller than the tobacco combustion products,
and NRTs do not increase the risk of cancer [22]. Notably, nico-
tine is contra-indicated in pregnant women because it may
cause premature birth and in youths as it affects the devel-
oping brain [17]. However, for most smokers addicted to nicotine,
an inhaler delivering pure nicotine to the lungs may be pre-
ferred and more effective than either e-cigarettes or current
NRTs to aid in smoking cessation.A nicotine inhalation product
that is economical, simple to use and tailored to the needs of
smokers [23], which delivers a consistent dose of nicotine to
the deep lung in one or two puffs, has the potential to address
the limitations of current NRTs. The opportunity for inhaled
NRTs is discussed in this review.
2. Requirements for an effective nicotine
inhaler
The large number of smokers who are unable to quit repre-
sents a significant market opportunity for an effective smoking
cessation product, not only in terms of product sales but also
with respect to the positive healthcare benefit to individuals
and society at large.A properly-designed inhaler providing nico-
tine pharmacokinetics similar to that for cigarettes has the
potential to address a number of the acceptability issues with
the currently marketed NRTs [24]. Previous attempts with ‘nico-
tine inhalers’ including metered dose inhalers failed due to
upper airway irritation, poor deep lung delivery, and formu-
lation problems [9]. So it is critical that the performance of the
inhaler be designed to minimize delivery of nicotine aerosol
to the oropharynx and upper airways, and ensure that a re-
producible and effective dose reaches the deep lung. This can
be achieved by proper control of the primary parameters which
affect deposition in the oropharynx and lung, the inhalation
flow rate and aerosol particle size distribution. Other factors
are also important including the timing and length of the
aerosol generation process, proper coordination of the inha-
lationmaneuver with onset of aerosol delivery and the potential
for particle growth or evaporation during transit.
Deposition of a significant fraction of the nicotine aerosol
in the oral cavity will provoke cough leading to poor product
acceptability [9]. In addition, coughing interrupts the inspira-
tion maneuver and so results in low or inconsistent delivery
of the nicotine aerosol to the deep lung. High oropharyngeal
deposition and its inherent aversive response is what torpe-
doed the early attempts to use nicotine metered dose inhalers
(MDIs) [9]. Particle deposition in the oropharynx is primarily
due to inertial impaction which increases with both particle
size and inhalation flow rate; together these two factors impart
greater momentum to particles [25]. Thus, a properly de-
signed nicotine inhaler can overcome this challenge by
producing aerosols with predominantly small droplets, typi-
cally with aerodynamic diameters less than ~5 μm, inhaled at
relatively slow flow rates; e.g., <30 l/min [25].
An additional requirement is to deliver a consistent and ef-
fective dose of nicotine to the deep lung where it can rapidly
be absorbed into the bloodstream,which drives delivery of high
peak nicotine concentrations to the brain.An outcome of avoid-
ing significant deposition of nicotine in the oral cavity is that
the majority of the generated aerosol has the potential to
deposit in the deep lung; however, very small particles may
be exhaled (and that is the primary reason that secondhand
exposure to cigarette smoke is such a concern) [25]. To cir-
cumvent exhalation of particles, the aerosol particles should
be greater than ~1 μm [25,26].Thus, an aerosol between around
1 and 5 μm, inhaled at a slow flow rate, is required for deep
lung deposition and rapid absorption of nicotine.
Furthermore, the nicotine dose delivered to the lung should
be adequate to achieve peak blood levels of nicotine comparable
to that for cigarettes; e.g., a mean of 19 ng/ml [27] to 26 ng/ml
[28] was reported for venous and 35 ng/ml [29] for arterial blood
sampling. If the inhaler does not deliver the nicotine to the
deep lung, or is not formulated for rapid absorption, then it
will be difficult to achieve these nicotine levels in a comparable
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time frame to cigarette smoking; i.e., 1–5 min. For example, sys-
temic nicotine PK profiles from e-cigarettes more closely
resemble those from nicotine patches [30]. For some e-cigarettes
the systemic levels of nicotine did not increase from base-
line, indicating that no meaningful absorption of nicotine had
taken place [27]. Using the newer generation of e-cigarettes,
continuous vaping for at least 35 min was required to achieve
the peak blood levels that are achieved in less than five min
from cigarettes (Fig. 3). For the older generation of e-cigarettes
these levels were not achieved even after 65 min of vaping
(Fig. 3).
Thus, the properly designed inhaler described above must
reproducibly generate an aerosol with a uniform and narrow
particle size distribution containing a consistent nicotine dose
in those particles, and further, the particles must be ad-
equately small and the inhalation flow rate adequately slow
to avoid appreciable oropharyngeal deposition [31]. The nico-
tine formulationmust also be designed so that there is no delay
in the uptake of the drug across the lung. For other inhaled
products the choice of salt form, excipients, buffer pH, or vehicle
can reduce the rate of drug dissolution, which would lead to
lower systemic peak drug concentrations [32]. These factors
must also be considered for a nicotine formulation.The physi-
cal state of the drug and the size and surface area of the
delivered particles can also affect the dissolution rate and thus
systemic uptake. Even the choice of inhaler can affect the rate
of transport across epithelial cells; e.g. the more crystalline drug
particles in one salbutamol dry powder inhaler (DPI) led to
slower uptake compared to the amorphous particles gener-
ated by the MDI [32]. Excipients can be added to the nicotine
formulation to attenuate the aversive response (e.g., the tar in
cigarettes serves this purpose by ‘coating’ the nicotine), but
these excipients should be selected with care as they can also
lead to slower uptake across the lung and thus lower sys-
temic peak nicotine levels. Furthermore, there is the possibility
for overdosing if the aversive sensation is completely elimi-
nated, or if there is a delay in absorption, combined with the
consumer inhaling additional doses with the mistaken belief
they did not receive an effective dose.
3. Inhaled nicotine replacement therapies in
development
3.1. The AERx essence pure nicotine inhaler (Aradigm,
Hayward, CA)
The AERx platform of inhalation devices has been tested in
thousands of patients under US Investigational New Drug (IND)
Applications for a variety of drug and biologics products and
no safety issues have been associated with the platform [26].
The key reason for the safety is that the formulations typi-
cally consist of a small amount (~50 μl) of an aqueous solution
of drug or biologic, free of organic solvents and innocuous
chemicals. The specific platform used for delivering nicotine
is based on the palm-size prototype called the AERx Essence,
which was tested in several clinical trials including one with
nicotine [26,33]. The follow-on AERx nicotine inhaler is de-
signed to be about the size of a small smart phone – which
has been proven to be the size of arguably the most popular
consumer product on a global scale. It does not produce any
“second-hand smoke”, in contrast to cigarettes or e-cigarettes.
The AERx nicotine inhaler does not require any batteries or
external power [26].
The AERx nicotine inhaler consists of a durable purely-
mechanical device and a single dose disposable dosage form
(strip) containing the nicotine formulation (Fig. 4A). The for-
mulation consists of pharmaceutical grade stable nicotine salt
solution in pure water as the only other excipient [10,24]. The
operation of the device involves simply opening the device, in-
serting the nicotine strip, closing the device, initiating inspiration
and pushing the button to actuate delivery in a single breath
[26]. The inhaler synchronizes generation of the aerosol with
the initiation of inspiration and it also controls the flow rate
during inhalation to ensure that a reproducible dose is deliv-
ered [26].
The in vitro performance of the AERx Essence system (4 pro-
totype devices that were used in the clinical trial in smokers
described below) was characterized across a range of nico-
tine concentrations from 5 to 40 mg/ml with a linear response
in nicotine delivered dose versus loaded dose (r2 = 0.99) [13].
Strips were filled with a nicotine salt (nicotine bitartrate) dis-
solved in water at pH 3.0–3.1. The formulations were placed
on stability at 25 °C and 40 °C for 9 months, with no forma-
tion of nicotine degradation products, no changes in pH and
no meaningful changes in nicotine concentration or aerosol
performance [13]. The 10, 20 and 30 mg/ml nicotine concen-
trations translate to a device loaded dose of 0.5, 1.0 and 1.5 mg
nicotine. The aerosol particle size distribution was relatively
insensitive to nicotine concentration with a mass median aero-
dynamic diameter (MMAD) ranging from ~2.4 to ~2.8 μm for
the 10–30 mg/ml nicotine concentrations, respectively, with a
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Fig. 3 – Nicotine plasma profiles for the first generation
electronic cigarette (i.e., cigarette-like) and the newer
generation of electronic cigarettes (i.e., containing
high-capacity batteries with electronic circuits that provide
high energy to a refillable atomizer) compared to cigarettes.
The first generation electronic cigarette represents a V2
standard Cig with cartomizer, while the newer generation
electronic cigarette represents an EVIC set at 9 watts with
EVOD atomizer. The nicotine pharmacokinetic data are
adapted from Reference 12 for cigarettes and Reference 30
for the E-cigarettes. Data for the electronic cigarettes
represent the mean of n = 23 smokers.
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geometric standard deviation (GSD) of 1.3 for both [13]. The
amount of emitted aerosol in particles less than 4.95 μm in size,
termed the fine particle dose, was 0.23, 0.48 and 0.73 mg, for
the 0.5, 1.0 and 1.5 mg loaded dose, respectively [13]. The fine
particle dose is a reliable estimate of the dose that deposits
in the lung [33].The highest AERx nicotine dose of 0.73 mg thus
represents about 50% of the 1–2 mg lung dose from a typical
cigarette. While a cigarette is typically inhaled over seven to
ten puffs, for the AERx nicotine inhaler the dose is given in a
single inhalation.
The pharmacokinetics (PK) of inhaled nicotine from theAERx
Essence device was studied in a phase 1 human clinical trial
in 18 participants [10].The PK profiles for all three nicotine doses
from a single inhalation show a maximum arterial blood level
at the first time point, 1 min post administration (Fig. 5). The
nicotine levels decrease from the peak over time to produce
profiles comparable to that for cigarettes (Fig. 5). An increase
in the nicotine dose, from 0.23 to 0.73 mg, resulted in an in-
crease both in the peak (Cmax) and extent of absorption (AUC),
with a trend toward dose proportionality [13].
The efficacy of the same three dose levels was also evalu-
ated in a subset of subjects (n = 16) by monitoring their craving
levels on a 10 point visual analog scale (with a score of 0 rep-
resenting no craving at all and 10 representing most craving
ever) prior to administration of the inhaled nicotine and then
for the next 4 h [13]. For all three dose levels the initial craving
score was between 4 and 6, indicating a moderate desire to
smoke (Fig. 6).The craving score immediately decreased by 3–4
units at the first time point (2 min) following dosing and re-
mained low (below 3) for 60 min for all three dose levels (Fig. 6)
and remained below pre-baseline craving levels for 4 h, which
was the end of the study [13]. Nearly all subjects reported an
acute reduction in craving or an absence of craving immedi-
ately following study dosing. While the craving was acutely
reduced, in line with the appearance of rapid peak systemic
nicotine plasma levels, there did not appear to be a dose re-
sponse across the three nicotine levels (Fig. 6). This result
suggests that a lower nicotine dose than in cigarettes may be
effective as an NRT.
Regarding safety measures (e.g., vital signs, ECG, spirom-
etry, and labs (full blood count, renal function tests, glucose,
liver function tests, alkaline phosphatase, serum electro-
lytes, and urine macro panel and microscopy)), no clinically
significant changes were observed following dosing. Mild and
moderate acute adverse events were noted, typically involv-
ing cough, throat irritation or light-headedness, similar to the
effects of nicotine from cigarette smoking, and these self-
resolved without medication.Thus, inhaled nicotine across the
0.23–0.73 mg range using the AERx Essence system appears safe
and tolerable with a PK profile that is consistent with the rapid
delivery and absorption of nicotine observed with cigarettes.
3.2. Voke® nicotine metered dose inhaler (Kind Consumer
Ltd., London, UK)
The Voke System (Fig. 4B) is a nicotine delivery device based
on metered dose inhaler (MDI) technology and comprises an
MDI reservoir and a ‘stick’ that delivers the nicotine to the
subject [13,34–36].The MDI reservoir contains 20 doses of 0.056%
(w/w) nicotine formulated in propylene glycol, ethanol,
(A)
(B)
(C)
Fig. 4 – Images of the three devices and schematics of their
operation (where available) discussed in this article. (A) An
image of the AERx Essence System including the
hand-held device and the nicotine dosage form. (B) A
comparison of the operation of the Voke Inhaler to that of
an electronic cigarette. (C) A schematic of the aerosol
generation process from the Staccato Inhaler (from
http://www.alexza.com/staccato/staccato-platform).
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saccharin, menthol, and HFA134a propellant. The number of
doses is patterned after cigarettes which contain 20 ciga-
rettes per pack. The ‘stick’ is charged with nicotine from the
MDI and the subject inhales 6–8 times from the ‘stick’ to receive
the complete dose of 0.43 mg nicotine. The stick is triggered
to deliver the nicotine aerosol within 0.5 s upon inhalation at
a flow rate of at least 2–3 l/min [34,35], comparable to inspi-
ratory flows smokers typically draw when smoking cigarettes.
This is in contrast to pharmaceutical MDIs which are typi-
cally inhaled at much faster flow rates of 60 l/min [25]. The in
vitro performance of theVoke has been characterized with the
mean emitted dose falling within 75–125% of the 0.43 mg nico-
tine nominal dose, even after storage for up to 18 months at
25 °C/60% RH or 30 °C/65% RH [34]. The fraction of the aerosol
less than 5 μm, termed the fine particle fraction (FPF), was 80%
of the emitted dose, yielding an in vitro fine particle dose (FPD)
of 0.29–0.37 mg nicotine per complete dose from the stick.
The pharmacokinetics of theVoke nicotine inhaler has been
tested in 18 smokers (who smoke ≥10 cigarettes/d with their
first cigarette within an hour of waking) in a Phase 1 human
clinical trial [13,36]. Three doses were evaluated: 0.22, 0.45 and
0.67 mg nicotine, which were delivered in 6–8 puffs over a 2 min
period [13,36]. The mean maximum arterial nicotine concen-
tration for the 0.22, 0.45 and 0.67 mg nicotine doses was 2.11,
3.73, and 4.38 ng/ml, respectively, which was achieved after 10.2,
7.3, and 6.5 min from the start of inhalation for each of the three
doses, respectively (Fig. 5) [13]. In contrast to the Nicorette® In-
halator, for which the nicotine is absorbed bucally and results
in earlier and higher venous than arterial nicotine levels, the
Voke inhaler has earlier and higher arterial nicotine levels than
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Fig. 5 – Mean arterial nicotine levels for the AERx Essence System and the Voke Inhaler. The pharmacokinetic profiles are
adapted from References 10 and 13. The sample sizes are n = 5, 6, and 5 for AERx 0.73, 0.48 and 0.23 mg nicotine,
respectively [10], and n = 6 for all three Voke groups [13].
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477a s i an j o u rna l o f p h a rma c eu t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 4 7 2 – 4 8 0
venous levels, suggesting more pulmonary nicotine absorp-
tion [13]. However, the peak arterial nicotine concentration using
the Voke inhaler represents only 5–10% of what is typically
achieved from smoking one cigarette, likely due to slower ab-
sorption of nicotine from the Voke inhaler compared to that
for cigarettes [13].
The participants in the study (n = 24) were also evaluated
for the ability of the nicotine dose (0.45 or 0.67 mg) to reduce
their craving for smoking compared to the Nicorette Inhala-
tor, which delivers ~4 mg nicotine (Fig. 6) using a visual analog
scale with a score of 0 representing no craving and 10 repre-
senting strong craving [36]. Craving scores for both doses from
the Voke Inhaler showed a drop at the first time point tested,
4 min post administration, which were comparable to the drop
for the approved Nicorette Inhalator.The craving scores for the
0.45 mg Voke dose and the Nicorette Inhalator both reached
a nadir at the 20 min time point post administration (Fig. 6)
and gradually increased back to their pretreatment values over
the subsequent 280 min [36]. In spite of the 50% lower overall
nicotine exposure from the 0.45 mgVoke inhaler, it was at least
as effective as the Nicorette Inhalator in reducing craving scores
and superior at some time points post dose (reaching statis-
tical significance at the 180 and 240 min time points) [36].
In both the PK and craving efficacy element of the trial a
number of adverse events were reported,mostly related to study
medication [13,36]. In the pharmacokinetic substudy there were
a total of 56 adverse events in 16 (89%) subjects including oral
paresthesia, throat irritation, headache, dizziness, dry throat
and cough [13]. Tolerability symptoms were reported in two-
thirds of the subjects [13]. In the craving substudy, a total of
87 adverse events were reported in 23 (96%) participants, but
all were mild or moderate in nature, similar to those re-
ported in the PK substudy [36].
3.3. The staccato evaporative condensation system
(Alexza Pharmaceuticals, CA, USA)
The Staccato® system (Fig. 4C) is a hand-held device which de-
livers a condensation aerosol following rapid vaporization of
the drug from the drug-coated stainless steel substrate element
in the device [37]. The device is breath-actuated and delivers
aerosol, which is within the respirable size range of 1–5 μm [37].
The device incorporates a valve to control the inhalation rate
and thus the rate of drug vaporization [37]. This technology is
already approved and marketed for delivery of loxapine for
acute treatment of agitation associated with schizophrenia or
bipolar I disorder [38].The Staccato system for delivery of nico-
tine is at an earlier stage of development and there is no human
safety or efficacy data [14].The deposition of drug in a film layer
on the substrate element is typically achieved by solubilizing
the drug in a solvent (ethanol, acetone, chloroform, hexane or
methanol) and applying it by a spray coating process [37]. For
drugs like nicotine which are liquids at ambient tempera-
tures, this process is not used. Instead, nicotine is complexed
with a zinc halide (ZnBr2(nicotine)2 and ZnCl2(nicotine)2) to fa-
cilitate spray coating [14]. The Staccato system was able to
achieve an emitted dose of nicotine of ~100 μg, comparable to
that in a single puff from a cigarette [14]. However, 43% of the
emitted nicotine was in a vapor form, and the other 57% in
particle form had a mean particle size of 0.8 μm (Volume Mean
Diameter), suggesting that much of the dose would be exhaled.
There are no published reports of the performance of this
system for delivery of nicotine in animals or humans.
4. Results and discussion
Interest in developing an inhaled NRT that is effective for people
wanting to quit smoking has escalated, in line with the growing
popularity of e-cigarettes. A number of inhaled nicotine de-
livery systems were reviewed in this article.The Staccato system
containing the drug loxapine for the treatment of psychotic
episodes is on the market and provides rapid and reproduc-
ible systemic absorption following inhalation with a Tmax of
2 min [38], suggesting that it may also have the potential to
deliver inhaled nicotine rapidly to the bloodstream. However,
there is no published inhalation safety data on the nicotine
metal complex used in the Staccato formulation, nor whether
inhaled nicotine is well-tolerated and rapidly absorbed from
this system, which is a requirement of an effective smoking
cessation product. The Staccato technology has potential for
use as an NRT but more preclinical and clinical data are needed
to make an informed evaluation.
A recent review article concludes that “inhalers can deliver
nicotine more efficiently than other nicotine products, facili-
tating smoking cessation and improving smoker’s lives” [9].
Those authors conducted a phase 1 clinical trial with a metered
dose inhaler product, different from theVoke inhaler, but found
similar PK profiles with a slower Tmax (5–6 min) than for ciga-
rettes (2 min), indicating that most of the nicotine in the MDI
aerosol was absorbedmore slowly via the oropharynx and upper
airway [28]. This MDI was able to achieve higher peak nico-
tine concentrations than for the Voke inhaler of 9.4–12.5 ng/
ml for the two dose levels (0.5 and 1 mg, respectively), but are
still lower than that for the cigarette (25.9 ng/ml) [28].To achieve
these peak nicotine levels, it was necessary to administer twenty
inhalations from the MDI spacer over a 5 min period [28]. The
bioavailability was 19.5% (0.5 mg) and 35% (1.0 mg) for the MDI
compared to the 1.1 mg nicotine content delivered by the ciga-
rette [28]. Even though significant discomfort (e.g., coughing
and interruption in inspiratory flow) was reported by the par-
ticipants, both doses also reported reductions in craving [28].
While the Voke inhaler appears to be in a more portable and
pleasing format for smokers, this MDI and spacer were in a
traditional pharmaceutical presentation and would likely need
to be redesigned for the smoking cessation market.
While there appear to be limitations with both MDI prod-
ucts discussed above, including aversive aerosols, extended
administration times, and delayed (and low) peak PK pro-
files, they support the concept that a nicotine inhaler can
provide a reduction in craving for cigarettes. The Voke Inhaler
(0.45 mg nicotine) recently received a product license for general
sale from the UK Medicines and Healthcare Products Regula-
tory Agency (MHRA) and may reach consumers in 2015 [39].
The license is for the relief and/or prevention of craving and
nicotine withdrawal symptoms associated with tobacco de-
pendence.The indication includes smokers wishing to quit or
reduce cigarette use prior to quitting, as well as situations where
smokers are unable to smoke, and as a safer alternative to
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smoking for smokers and those around them. The medical
device component of the Voke inhaler has also received the
CE mark that is required for medical devices sold in the Eu-
ropean Union.These approvals are necessary given the MHRA’s
2013 decision that all nicotine containing products sold in the
UK will require a license by 2016 [40].
In contrast, the craving for a cigarette can be satisfied in a
single breath from the AERx nicotine inhaler discreetly, in less
than one min. The PK profile from the AERx system reaches a
peak at the first blood draw of 1 min post administration, in-
dicating aerosol deposition in the deep lung facilitating rapid
absorption, comparable to the deposition and absorption profile
from cigarettes [13]. This rapid absorption of nicotine was as-
sociated with an immediate drop (2 min post dose) in the
craving score [13]. The duration of effect was prolonged,
remaining below pretreatment baseline levels for 4 h. Further-
more, all three doses had comparable reductions in craving
scores, suggesting the potential for the AERx nicotine inhaler
to be needed less often than for cigarettes, and exposing the
subject to only a fraction of the nicotine dose in cigarettes.
The AERx nicotine inhaler is purely mechanical, requiring
no batteries, no heating of the product, and will offer precise
control of delivery with extremely low probability of acciden-
tal overdose. Furthermore, the AERx nicotine inhaler will not
have the attraction to children that cigarettes and e-cigs do,
as it is a discrete product used once every few hours in con-
trast to the more frequent use of cigarettes and e-cigarettes.
The total daily dose of nicotine from the AERx nicotine inhaler
will likely be lower than for other NRTs (e.g., patches) and for
cigarettes. The delivery of nicotine using the AERx Essence
Inhaler may one-day offer a convenient, safe, effective and so-
cially acceptable alternative to smoking by satisfying periodic
craving episodes to help those whowant to quit smoking [10,24].
5. Conclusion
Given the marginal effectiveness of the current marketed NRTs
to facilitate smoking cessation, the market opportunity and so-
cietal benefit for an effective inhaled NRT is huge. An inhaled
NRT has the potential to provide the same physiological re-
sponse that smokers receive from cigarettes and so may
successfully address the craving episodes and other symp-
toms of nicotine withdrawal. Among the nicotine inhalers
covered in this review, the AERx Essence System is the only
nicotine inhaler that has demonstrated the ability to rapidly
deliver peak arterial nicotine levels in under a minute that are
comparable to those achieved during cigarette smoking. Ad-
ministration of inhaled nicotine from the AERx Essence System
was associated with a rapid and prolonged reduction in craving
for cigarettes for at least 2 h. These results suggest that an
inhaled nicotine system like the AERx Essence System, once
approved as an NRT, could be used by smokers as an aid for
smoking cessation.
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